Company news
Allogene Therapeutics, Inc. news in 2022
Allogene Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
November 28, 2022
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 9, 2022
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 2, 2022
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
November 1, 2022
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
October 30, 2022
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
October 25, 2022
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
October 10, 2022
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
October 5, 2022
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
September 22, 2022
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
August 8, 2022
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
July 11, 2022
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
June 7, 2022
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 18, 2022
Allogene Therapeutics Reports First Quarter 2022 Financial Results
May 3, 2022
Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
April 27, 2022
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
April 26, 2022
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
April 13, 2022
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
March 22, 2022
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
March 9, 2022
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 22, 2022
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
January 10, 2022
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
January 9, 2022
Calls in 2022
- Allogene Therapeutics (NASDAQ:ALLO) Q3 2022 Earnings Call
Nov 2, 2022
Transcript - Allogene Therapeutics (NASDAQ:ALLO) Q2 2022 Earnings Call
Aug 9, 2022
Transcript - Allogene Therapeutics (NASDAQ:ALLO) Q1 2022 Earnings Call
May 4, 2022
Transcript - Allogene Therapeutics (NASDAQ:ALLO) Q4 2021 Earnings Call
Feb 23, 2022
Transcript
Decks in 2022
- Technical Presentation (December 2022)
Technical · 9 slides · Dec 1, 2022